This webcast is based on a roundtable discussion on the optimal diagnosis and future management of lysosomal diseases. Three experts specializing in Fabry, Gaucher, and Pompe disease will raise key clinical questions and discuss how to overcome barriers in daily clinical practice across the lysosomal disease spectrum. The experts will provide an update on the long-term effects of ERT and highlight the remaining challenges, including the consequences of delayed diagnosis. They will discuss the role and importance of early diagnosis and treatment initiation, and provide perspectives on the recent advances in screening programs for newborn and high-risk populations. Lastly, the experts will address the position of emerging therapies and strategies for the optimal management of lysosomal diseases.
From Alzheimer's to Epilepsy and Multiple Sclerosis Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of neurology activities.
Welcome to Progress in Spinal Muscular Atrophy (SMA) Management, an Elsevier Learning Center. This learning center is a freely accessible platform that aims to increase clinical knowledge by providing Continuing Medical Education (CME) activities, research articles, and resources for health care professionals (HCPs) who treat patients with spinal muscular atrophy (SMA).
The American Headache Society (AHS) 60th Annual Scientific Meeting was held in San Francisco, California, June 28-29, 2018. The mission of AHS is to improve the care and lives of people living with headache disorders. AHS is a professional society of health care providers dedicated to the study and treatment of headache and face pain. The Society’s objective is to promote the exchange of information and ideas concerning the causes and treatments of headache and related painful disorders. Educating physicians, health professionals, and the public, and encouraging scientific research are the primary functions of the Society. AHS activities include an Annual Scientific Meeting, a comprehensive headache symposium, regional symposia for neurologists and family practice physicians, publication of the journal Headache, and sponsorship of the American Migraine Foundation.
*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.
Dravet syndrome (DS), a rare form of epilepsy, occurs in approximately 1 in 20,000 live births and is associated with a significant humanistic and economic burden on caregivers, families, and patients. While many medications are used in treating the seizures associated with DS, there are currently no FDA-approved treatments, and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Several investigational therapies are in late-stage development with the potential to provide new treatment options to address the serious medical needs for patients with DS.
This is a two-part CME activity with Part 1 highlighting real-world approaches to patient care utilizing design intelligent patients who have realistic and consistent human-to-human interaction and communication skills, opening possibilities for clinical psychosocial applications that address interviewing skills, diagnostic assessment and therapy training. The platform provides real-time feedback for continuous assessment and creates a personalized learning experience by presenting learners with data regarding their performance against peers. Part 2 of this activity is an Expert Exchange webcast that provides learners with a concise educational experience featuring two clinical experts exploring real-world approaches to patient care.
The AAT-AD/PD™ Focus Meeting 2018 was held in Turin, Italy, March 15-18, 2018. During the new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) and AD/PD,TM the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer's, Parkinson's, and other related neurological disorders were at the forefront of the meeting. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.
The American Academy of Neurology (AAN) Annual Meeting was held in Los Angeles, California, April 21-27, 2018. The AAN annual meeting is the largest international gathering of neurologists and neuroscience professionals. In this activity, 2 experts summarize the key learnings from this year’s conference focusing on Alzheimer’s disease (AD).
This webcast is based on a discussion between two leading experts in the field of spinal muscular atrophy (SMA) who exchange views on “The 2017 Update of the Standard of Care Recommendations for SMA”. They summarize and review the current best practices for diagnosis, multidisciplinary care, physical therapy, orthopedic care, nutrition, pulmonary care, and acute care and discuss how novel treatment options such as newly approved medications have impacted the outlook for patients and are changing the care setting. The experts provide an outlook on how developments such as newborn screening will influence the future of SMA management.
This webcast was recorded during a live symposium at the WORLDSymposium Meeting in San Diego, CA, USA, on February 7, 2018. During the symposium, experts from around the world discussed the key clinical questions and controversies in the diagnosis of Fabry disease and the future direction of clinical management. They also addressed the consequences of delayed diagnosis and treatment initiation, provided guidance on understanding available diagnostic options, and discussed genotype–phenotype correlations and their significance for daily clinical practice.
How Gene Replacement Therapy is Changing the Way We Manage Spinal Muscular Atrophy and Other Neurologic DiseasesFormat: Supplement
Innovations in technology, delivery, and vector systems in gene therapy mean that patients with potentially devastating neuromuscular disorders, such as spinal muscular atrophy (SMA), are now candidates for treatment. As these therapies emerge, clinicians need to understand how they work and associated broader implications for disease management. This supplement reviews the mechanisms by which viral vector systems correct gene defects and corresponding protein deficits, and discusses findings from recent and ongoing clinical trials. In addition, the authors—all experts in SMA—provide commentary on related topics and respond to frequently asked questions about SMA and gene replacement therapy.